New drugs counter neural inflammation in Parkinson’s
October 17, 2012
Researchers at the University of Alabama at Birmingham (UAB) have identified a set of experimental drugs called LRRK2 inhibitors that may go beyond symptom relief to directly counter the inflammation and nerve cell death at the root of Parkinson’s.
These effects have been suggested in mouse and cell culture studies meant to approximate human disease.
Most Parkinson’s disease (PD) patients are still treated with a 42-year-old drug called L-DOPA, which… read more














